ALNY Stock Forecast: Alnylam Pharmaceuticals, Inc. Price Predictions for 2026-2027
The 30 Wall Street analysts covering Alnylam Pharmaceuticals, Inc. hold a median 12-month price target of $287 — +99.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 58 of 100 as at 21 Nov 2026 — in the upper half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Alnylam Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (99): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Accruals (10): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
ALNY stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on ALNY, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +99.8% from it.
Of the 20 most recent actions, 1 moved their price target up and 18 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 20 Nov 2026 | BMO Capital | Maintains | Outperform | $292 → $293 |
| 17 Nov 2026 | Cantor Fitzgerald | Maintains | Neutral | $290 → $205 |
| 17 Nov 2026 | HC Wainwright & Co. | Maintains | Buy | $455 → $250 |
| 2 Nov 2026 | Barclays | Maintains | Overweight | $450 → $380 |
| 2 Nov 2026 | Canaccord Genuity | Maintains | Buy | $429 → $323 |
| 2 Nov 2026 | Truist Securities | Downgrade | Hold | $315 → $225 |
| 31 Oct 2026 | UBS | Maintains | Buy | — |
| 30 Oct 2026 | Bernstein | Downgrade | Market Perform | $376 → $199 |
| 30 Oct 2026 | Goldman Sachs | Maintains | Buy | $536 → $320 |
| 30 Oct 2026 | Morgan Stanley | Maintains | Equal-Weight | $300 → $240 |
| 30 Oct 2026 | Raymond James | Downgrade | Outperform | $420 → $315 |
| 30 Oct 2026 | RBC Capital | Maintains | Outperform | $345 → $280 |
| 30 Oct 2026 | TD Cowen | Maintains | Buy | $482 → $354 |
| 30 Oct 2026 | UBS | Maintains | Buy | $354 → $329 |
| 30 Oct 2026 | Wells Fargo | Maintains | Equal-Weight | $253 → $220 |
| 29 Oct 2026 | Needham | Maintains | Buy | $357 → $243 |
| 15 Oct 2026 | UBS | Assumes | Buy | $550 → $354 |
| 14 Oct 2026 | Citigroup | Maintains | Buy | $340 → $320 |
| 14 Oct 2026 | Wells Fargo | Maintains | Equal-Weight | $256 → $253 |
| 8 Oct 2026 | RBC Capital | Maintains | Outperform | $350 → $345 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for ALNY.
This page is one stock. Monday covers all of them.
ALNY appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
ALNY vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Alnylam Pharmaceuticals, Inc. returned −67.8% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
ALNY analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 7.5×
- Price / sales
- 3.8×
- Price / book
- 5.3×
- EV / EBITDA
- 18.1×
Cheaper than 81% of US stocks
Cheaper than 28% of US stocks
Cheaper than 17% of US stocks
Cheaper than 24% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- 640.5%
- Gross margin
- 76.9%
- Operating margin
- 19.5%
- Net margin
- —
Higher than 96% of US stocks
Higher than 89% of US stocks
Higher than 79% of US stocks
- Return on equity
- 138.1%
- Return on assets
- 9.5%
- Dividend yield
- —
Higher than 97% of US stocks
Higher than 91% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Alnylam Pharmaceuticals, Inc. has a market value of $19.3B and an enterprise value of $18.7B.
Revenue in the twelve months to 30 June 2026: $4.8B. The latest quarter grew 66.9% year on year.
Net income over the same four quarters: $808.0M, a 16.8% net margin.
Diluted earnings per share, trailing twelve months: $5.38.
Free cash flow in the twelve months to 30 June 2026: $819.9M.
Trailing P/E: 7.5×; forward P/E: 14.5× — the forward figure prices analyst consensus estimates, not reported earnings.
Alnylam Pharmaceuticals, Inc. employs 2,500 people — $1.9M of revenue per employee.
Data provided by Twelve Data
ALNY and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at ALNY’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Alnylam Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about ALNY
What is the ALNY stock price forecast for 2026-2027?
The 30 Wall Street analysts covering Alnylam Pharmaceuticals, Inc. have a median 12-month price target of $287, with estimates ranging from $180 to $410. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is ALNY stock a buy right now?
Of the 30 analysts covering Alnylam Pharmaceuticals, Inc., 21 rate it a Buy, 9 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Alnylam Pharmaceuticals, Inc. 58 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank ALNY?
As at 21 Nov 2026, Alnylam Pharmaceuticals, Inc. ranks 58 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Value (99 of 100).
Will ALNY stock go up?
No one can know that. What the data says: the median 12-month target from 30 analysts implies +99.8% from the last close, and Ticker Nerd's factor model ranks Alnylam Pharmaceuticals, Inc. 58 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the ALNY stock forecast for 2030?
No analyst covering Alnylam Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ALNY are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $180 to $410 over the next 12 months.
How has ALNY stock performed over the past year?
Alnylam Pharmaceuticals, Inc. returned -67.8% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Alnylam Pharmaceuticals, Inc. do?
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on RNA interference therapeutics. Alnylam Pharmaceuticals develops, manufactures, and commercializes medicines designed to silence disease-causing genes, with a primary emphasis on rare genetic and cardiometabolic conditions.
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on RNA interference therapeutics. Alnylam Pharmaceuticals develops, manufactures, and commercializes medicines designed to silence disease-causing genes, with a primary emphasis on rare genetic and cardiometabolic conditions. Its current portfolio includes approved therapies for transthyretin-mediated amyloidosis, and the company also advances programs in areas such as hypertension and other genetically defined diseases. Alnylam Pharmaceuticals works across the United States, Europe, and other international markets, supporting patients through specialized treatments and healthcare partnerships. Headquartered in Cambridge, Massachusetts, Alnylam Pharmaceuticals plays a significant role in the growing RNAi medicine segment, where it is recognized for translating gene-silencing science into commercial therapies for serious conditions.
CEO Dr. Yvonne L. Greenstreet M.B.A., M.D. · 2,500 employees · United States · https://www.alnylam.com